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Abstract
Inositol stereoisomers, myo- and scyllo-inositol, are known to enter the brain and are significantly elevated following oral
administration. Elevations in brain inositol levels occur across a concentration gradient as a result of active transport from
the periphery. There are two sodium/myo-inositol transporters (SMIT1, SMIT2) that may be responsible for regulating brain
inositol levels. The goals of this study were to determine the effects of aging and Alzheimer’s disease (AD)-like amyloid
pathology on transporter expression, to compare regional expression and to analyze substrate requirements of the inositol
transporters. QPCR was used to examine expression of the two transporters in the cortex, hippocampus and cerebellum of
TgCRND8 mice, a mouse model of amyloid pathology, in comparison to non-transgenic littermates. In addition, we
examined the structural features of inositol required for active transport, utilizing a cell-based competitive uptake assay.
Disease pathology did not alter transporter expression in the cortex or hippocampus (p.0.005), with only minimal effects of
aging observed in the cerebellum (SMIT1: F2,26=12.62; p=0.0002; SMIT2: F2,26=8.71; p=0.0015). Overall, brain SMIT1 levels
were higher than SMIT2, however, regional differences were observed. For SMIT1, at 4 and 6 months cerebellar SMIT1 levels
were significantly higher than cortical and hippocampal levels (p,0.05). For SMIT2, at all three ages both cortical and
cerebellar SMIT2 levels were significantly higher than hippocampal levels (p,0.05) and at 4 and 6 months of age, cerebellar
SMIT2 levels were also significantly higher than cortical levels (p,0.05). Inositol transporter levels are stably expressed as a
function of age, and expression is unaltered with disease pathology in the TgCRND8 mouse. Given the fact that scyllo-
inositol is currently in clinical trials for the treatment of AD, the stable expression of inositol transporters regardless of
disease pathology is an important finding.
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Introduction
scyllo-Inositol is currently in human clinical trials for the
treatment of patients with mild to moderate Alzheimer’s disease
(AD; www.clinicaltrials.gov). This stemmed from preclinical
studies, in which scyllo-inositol was shown to be an effective
treatment for AD-like amyloid pathology and cognitive deficits in
TgCRND8 mice [1,2]. TgCRND8 mice show many of the
hallmark features of AD, including an increase in cerebral Ab
levels, Ab aggregation and plaque deposition, along with cognitive
deficits as the disease advances [3]. scyllo-Inositol treatment
significantly improved spatial memory, synaptic function and
survival rates in TgCRND8 mice [1]. These positive effects
occurred both in animals given scyllo–inositol prophylactically,
before the visible onset of symptoms, and therapeutically, once
symptoms had fully developed [1,2]. Gas chromatography/mass
spectrometry results found ad libitum scyllo-inositol treatment
increased scyllo-inositol levels within the brain 7-fold [2] and
magnetic resonance spectroscopy also demonstrated a 2 to 3-fold
increase in brain scyllo-inositol levels [4] suggesting that the
beneficial effects are centrally induced.
scyllo-Inositol is found endogenously in the body and is the
second most abundant inositol stereoisomer [5,6]. The brain levels
of myo- and scyllo-inositols are 100-fold greater than those found in
the periphery [5,7]. This indicates that active transport, in
addition to simple diffusion, is required for the regulation of brain
inositol levels. Active transport of inositol stereoisomers across
cellular membranes including cells at the blood-brain and blood-
CSF barriers, occurs via inositol transporters. Two transporters,
SMIT1 and SMIT2, are important for regulating brain and
peripheral inositol levels, by co-transporting two sodium ions along
the concentration gradient, to generate enough energy to actively
transport myo-inositol [8–12]. While both transporters are
expressed in the brain [11,13,14], there is limited information
on the regional expression of these transporters and no data on
expression changes with various disease pathologies, including AD.
In addition, there is little information on age-induced changes to
transporter expression or comparative data on expression of
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mRNA levels were examined in three brain regions: the cortex,
hippocampus and cerebellum, as a function of age, genotype and
Ab/amyloid related pathology. These brain regions were chosen
as the cortex and hippocampus are most affected in AD while the
cerebellum is only affected very late in the disease. Expression was
examined in both TgCRND8 mice and non-transgenic (Tg)
littermates at 2, 4 and 6 months of age. These ages were selected
because they correspond to pre-plaque deposition, mid-stage and
advanced AD-like amyloid pathology in TgCRND8 mice [3].
Further, transport assays were conducted to determine the inositol
structural features required to decrease myo or scyllo-inositol
transport through SMIT1/2. The aims of this study were to
extend our knowledge of SMIT1 and SMIT2 expression as a
function of age and disease pathology and to better understand
substrate transport through these transporters. Both of these
experimental aims were achieved.
Results
Inositol transporter expression as a function of age and
progressive amyloid deposition
scyllo- and myo-Inositol accumulate in the brain, at levels 100-fold
higher than those in the periphery [5,7], through active transport.
There are two sodium myo-inositol transporters that have been
reported in the literature, SMIT1 and SMIT2, both of which are
expressed in the brain [11,13,14]. Normal brain aging has been
linkedwith neuronalcell loss,an increase ingliosis and ultimately an
increase in both myo-a n dscyllo-inositol as shown by magnetic
resonance spectroscopy [15,16]. This increased inositol signal may
be due to increased transporter activity or expression. Therefore,
one goal of these experiments was to examine whether the levels of
these transporters change as a function of age. The mRNA
expression of the two inositol transporters was examined at 2, 4 and
6 months of age in both TgCRND8 mice and non-Tg littermates in
the cortex, hippocampus and cerebellum. Significant age effects on
transporter expression were observed in the cerebellum of both
groups (SMIT1: F2,26=12.62; p=0.0002; SMIT2: F2,26=8.71;
p=0.0015), but not in the cortex or hippocampus (p.0.05).In both
TgCRND8 mice (Figure 1) and non-Tg littermates (data not
shown), 2 month SMIT1 and SMIT2 levels were significantly lower
than 4 and 6 month levels (p,0.05). More specifically, in
TgCRND8 mice, 2 month, cerebellar SMIT1 levels were
significantly lower than 4 and 6 month levels (Figure 1A, C, E;
p,0.05) and 2 month, cerebellar SMIT2 levels were significantly
lower than 4 month levels (Figure 1B, D; p,0.05). In non-Tg
littermates, 2 month, cerebellar SMIT1 and SMIT2 levels were
significantly lower than 6 month levels (data not shown; p,0.05).
These regional differences, for the effects of age on expression, may
reflect the continual postnatal maturation of the cerebellum [17],
which does not occur in the cortex or hippocampus.
A comparison of SMIT1 and SMIT2 expression between
TgCRND8 mice and non-Tg littermate mice, at 2, 4 and 6
months of age, was used to determine the effects of AD-like
amyloid pathology on transporter expression. No significant
differences in SMIT1 or SMIT2 expression were observed
between TgCRND8 mice and non-Tg littermates at all ages and
in all regions, indicating that increasing amyloid pathology does
not alter the expression of the transporters (p.0.05; data not
shown).
Regional brain inositol transporter expression levels
The expression of SMIT1 and SMIT2 were quantified in the
cortex, hippocampus and cerebellum (Figure 1). These three brain
regions are affected to varying degrees by Ab plaque deposition in
AD [18]. The earliest plaque deposition is observed in the cortex
and hippocampus, while deposition in the cerebellum occurs very
late in the disease [18]. Both transporters were expressed in all
three brain regions examined, however regional differences in
expression for each transporter were observed. For both
transporters, a significant correlation between brain region and
transporter expression levels was found (Figure 1; SMIT1:
F2,86=14.86, p,0.0001; SMIT2: F2,86=55.04, p,0.0001). For
SMIT1, no significant differences in regional expression were
observed at 2 months (Figure 1A), but at 4 and 6 months,
cerebellar SMIT1 levels were significantly higher than cortical and
hippocampal levels (Figure 1C, E; p,0.05). For SMIT2, at all
three ages both cortical and cerebellar SMIT2 levels were
significantly higher than hippocampal levels (Figure 1B, D, F;
p,0.05) and at 4 and 6 months of age, cerebellar SMIT2 levels
were also significantly higher than cortical levels (Figure 1D, F;
p,0.05).
Structural requirements for inositol transport
Although SMIT1/2 transport of various inositol stereoisomers
has been reported, the structural requirements for transport have
not been examined. To define these parameters, transport of myo-
or scyllo-inositol-(2-
3H) was examined in the presence of 15 inositol
isomers, 6 hexoses and 2 pentose sugars which may serve as
competive substrates, inhibitors or allosteric effectors on inositol
transport (Figure 2). We first examined the myo- and scyllo-inositol
transport kinetics of our cell system (Figure 3). The transport of
myo-o rscyllo-inositol-(2-
3H) (100 mM) was assayed in the presence
of increasing concentrations of cold myo-o rscyllo-inositol. The
concentration dependence of myo-inositol saturated near 10 mM of
cold myo-inositol producing a near maximal inhibition of myo-
inositol-(2-
3H) transport, while half-maximal inhibition was
observed at 200 mM of cold myo-inositol (Figure 3A). As was seen
for myo-inositol, 10 mM of cold scyllo-inositol produced near
maximal inhibition of scyllo-inositol-(2-
3H) transport and half
maximal inhibition was observed at 200 mM cold scyllo-inositol
(Figure 3B). However, while the myo-inositol transport experiment
was conducted using a 15 minute incubation window, the scyllo-
inositol experiment required the incubation to be extended to
3 hours in order to produce similar uptake of scyllo-inositol. These
results highlight an apparent slower uptake rate for scyllo-inositol
by the transporters. Our half maximal inhibition values for myo-
inositol agree well with the range previously reported in the
literature; myo-inositol Km=55–117 mM for SMIT1 and
Km=120–348 mM for SMIT2 [9,10,19–24].
An examination of scyllo-inositol-(2-
3H) transport, in the
presence or absence of the 23 polyols, showed myo-, scyllo-, D-
chiro-inositol and L-fucose to significantly depress scyllo-inositol-
(2-
3H) transport (Figure 4; F23,48=14.47, p,0.05). In contrast,
when myo-inositol-(2-
3H) transport was tested in the presence or
absence of the 23 polyols, in addition to those identified for scyllo-
inositol, D-glucose, D-mannose, viburnitol, sequoyitol, D-ononitol
and D-pinitol also significantly depressed myo-inositol-(2-
3H)
transport (Figure 5; F23,48=18.46, p,0.05). This difference in
experimental findings likely stems from differences in the relative
transport rates of myo- and scyllo-inositol by SMIT1/2 and
differences in specificity of the transporters, which would result
in different observed inhibition profiles. Overall, our results are in
agreement with previous studies that identified myo-, scyllo-, D-chiro-
inositol, D-glucose and D-pinitol as substrate competitors
[9,10,19,22,24].
A comparison of the structural features of the compounds,
which depressed myo-inositol, allowed the design of a model of the
Inositol Transporters in AD-Like Pathology
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SMIT1/2 (Figure 6). With the panel of potential substrates tested,
this model is best used to identify compounds that will not be
recognized by the transporters, as additive effects between the
substituents cannot be determined. All of the active compounds
identified have equatorially positioned side chains at carbons 1, 2,
3 and 6, while the substituents at carbons 4 and 5 can be in either
orientation. In addition, a comparison of the substrate competitors
shows that the side group at position 1 can be either a hydroxyl,
hydrogen, or methyl group and the carbon can be exchanged for a
ring oxygen atom and maintain activity in the transport assay. At
position 2 either a hydroxyl or a methoxy side chain are tolerated.
At position 3, the hydroxyl group can be exchanged for a
hydrogen, methyl or methoxyl group, while at position 6, the side
chain must remain a hydroxyl group. At positions 4 and 5, either a
hydroxyl or a hydrogen group can be placed in either orientation
without disrupting the substrates competitive nature and the
carbon at position 4 can be exchanged for a ring oxygen atom.
Substrate recognition
We examined the recognition of the enantiomers D-chiro-
inositol, which depressed scyllo/myo-inositol transport through
SMIT1/2, and L-chiro-inositol, which had no effect, in greater
detail. To determine whether this enantiomeric change in
structure results in a complete lack of recognition by the
transporter or decreased transporter affinity, the effect of
increasing concentrations of each enanitomer on transport was
examined. L-chiro-inositol competed for myo-inositol-(2-
3H) trans-
port only at the highest concentrations assayed (160 mM),
consistent with our model and the previous assay carried out
using 10 mM L-chiro-inositol. In contrast, D-chiro-inositol demon-
strated a dose-dependent inhibition of myo-inositol transport
Figure 1. A comparison of regional expression for each of the inositol transporters. A comparison of the regional expression patterns of
SMIT1 (A, C, E) and SMIT2 (B, D, F) in the brain at 2 months (A, B), 4 months (C, D) and 6 months of age (E, F) showed a distinct pattern of
expression. SMIT1 levels were significantly higher in the cerebellum than in the cortex or hippocampus at 4 and 6 months of age. SMIT2 levels were
significantly higher in the cortex and cerebellum, compared to the hippocampus at all three time points and significantly higher in the cerebellum,
compared to the cortex, at 4 and 6 months of age. (n=10 animals/group; p,0.05).
doi:10.1371/journal.pone.0024032.g001
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the enantiomer of chiro-inositol recognized.
Based on our initial substrate transport studies L-fucose
decreases the rate of myo-inositol transport. Further analysis
confirmed this result showing that L-fucose reduced myo-inositol-
(2-
3H) transport in a concentration-dependent manner (Figure
S2A). To determine if L-Fucose was a competitive substrate for
SMIT or simply an inhibitor of the transporters the uptake of L-
fucose-(5,6-
3H) was measured. In these experiments no reduction
in cell associated L-fucose-(5,6-
3H) uptake was observed with any
of the inositol substrates tested (Figure S2B) and no changes in
radioactivity were observed in the presence of increasing
concentrations of cold L-fucose (Figure S2C). Therefore, we
propose that L-fucose is a SMIT1/2 transport inhibitor as has
been previously proposed [9,25].
The SMIT1/2 basic recognition model was further tested and
refined using a set of scyllo-inositol derivatives initially designed for
examination of the effects of scyllo-inositol derivatives on Ab
fibrillogenesis [26,27]. The use of these compounds allowed us to
address further the hydrogen-bonding requirements and steric
interactions between a given compound and the transporters.
Seven compounds were tested, in which either: one or two
hydroxyl groups were substituted with hydrogen or methoxy, or
one hydroxyl group was replaced with a fluorine, azide, or
chlorine (Figure 7A). Transporter recognition was observed
following the substitution of one hydroxyl group on scyllo-inositol
with a hydrogen atom or a hydroxy methyl group, however, the
substitution of two hydroxyl groups removed any recognition of
the compound by the transporters (Figure 7B). The finding that
1,4-di-O-methyl-scyllo-inositol was not transported is in agreement
with the SMIT1/2 model and suggests steric interference of the
bulky hydroxy methyl groups. Surprisingly, 1,4-dideoxy-scyllo-
inositol was also not recognized by the transporters, suggesting
that five hydroxyl groups or hydrogen bonding pairs are necessary
for transporter interaction. When the effects of substituting one
hydroxyl group were further examined, both 1-chloro- and 1-
fluoro-1-deoxy-scyllo-inositol competed as readily as myo-inositol for
active transport, while the hydrogen, azide and hydroxy methyl
substitutions were less effective (Figure 7B). These results suggest
that single small polar or non-polar substitutions on the scyllo-
inositol scaffold are tolerated but larger substitutions such as
methoxy or azide compromise transporter recognition.
Figure 2. Structures of the inositol stereoisomers, derivatives and related compounds. The structures of the inositol stereoisomers,
derivatives and related compounds used for the initial competitive transport assays.
doi:10.1371/journal.pone.0024032.g002
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scyllo-Inositol is present endogenously in both the body and the
brain [5,6], with brain levels 100-fold higher than those in the
periphery [5,7]. This points to the importance of active transport
for scyllo-inositol accumulation within the brain. Oral administra-
tion of ad libitum myo-o rscyllo-inositol to mice increased the
corresponding levels in the brain [2]. Both TgCRND8 mice and
their non-Tg littermates showed a significant increase in scyllo-
inositol levels in the brain following ad libitum administration, with
no significant differences observed in baseline or treatment-
induced brain inositol levels between the two groups [2]. In the
present study, no significant differences in SMIT1 or SMIT2
expression profiles were found between TgCRND8 mice and their
non-Tg littermates at any of the ages examined. Since the three
time points chosen correspond to pre-plaque deposition, early
plaque deposition and an advanced stage AD-like amyloid
phenotype [3], we can conclude that neither age nor amyloid
pathology alters SMIT1 or SMIT2 expression. A stable expression
pattern, irrespective of pathology, is an important factor for
successful scyllo-inositol treatment.
A comparison of SMIT1 versus SMIT2 expression in
subregions of the brain was also conducted. Although it is known
that both inositol transporters are expressed in the brain
[11,13,14], our study found differences in the relative expression
levels of the two transporters across brain regions that are affected
in AD. Overall, expression in the brain of SMIT1 was higher than
SMIT2. SMIT1 expression was observed in the order cerebel-
lum.cortex=hippocampus while SMIT2 expression was also
highest in the cerebellum.cortex.hippocampus. Both transport-
ers were expressed in all the brain regions examined.
The specificity and structural requirements for transport by
SMIT1/2 has not been previously investigated. To investigate the
recognition of inositol and sugars by the transporters a substrate
Figure 3. myo-Inositol and scyllo-inositol transport in HEK293 cells. myo-Inositol testing was conducted in HEK293 cells, by incubating cells
for 15 minutes in medium containing 100 mMo fmyo-inositol-(2-
3H) in the presence of increasing concentrations of cold myo-inositol (A). Addition of
10 mM of cold myo-inositol, the concentration used in the competitive transport assays, resulted in a near maximal inhibition of myo-inositol-(2-
3H)
transport in these cells. scyllo-Inositol testing was conducted over a period of 3 hours in these cells, due to slower uptake rates (B). Once again,
10 mM of cold scyllo-inositol produced near maximal inhibition of scyllo-inositol-(2-
3H). (n=3 wells per concentration).
doi:10.1371/journal.pone.0024032.g003
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and scyllo-inositol showed transport of scyllo-inositol to be
substantially slower despite the recognition of both substrates with
similar affinity (IC50 ,200 mM). An analysis of 23 different
inositols and sugars was conducted. Our findings indicate that a
number of substrates inhibit scyllo- and myo-inositol-(2-
3H)
transport. This inhibition could be due to direct competition for
transport, active inhibition of the transporters or through allosteric
inhibition. Specifically the SMIT1/2 transporters were found to
recognize D-chiro-inositol, viburnitol, D-glucose, D-mannose,
sequoyitol, D-ononitol and D-pinitol all to lesser extents than
myo-o rscyllo-inositol. Previously an equal preference for myo- and
scyllo-inositol was shown in Xenopus oocytes transfected with canine
SMIT1 [9]. SMIT1/2 transport of D-chiro-inositol [10,19,22,24]
and SMIT2 transport of D-glucose and D-pinitol have been
previously reported [24]. We confirm previous observations of
SMIT2 preference of these stereochemistries by the transporters
[19]. The HepG2 human liver cell-line was shown to preferentially
transport D-chiro-inositol and D-glucose over L-stereoisomers [19].
An additional substrate, L-fucose, has been previously identified as
a competitor for myo-inositol transport [9,25]. The present
observations that myo-inositol and increasing concentrations of
cold L-fucose did not reduce cell associated L-fucose-(5,6-
3H)
levels, allows us to conclude that L-fucose is a SMIT1/2 transport
inhibitor.
To further define transporter selectivity, novel derivatives of
scyllo-inositol, containing single or double hydroxyl group
substitutions were examined for transport. One or two hydroxyl
groups on scyllo-inositol were substituted with chlorine, fluorine,
hydrogen, azide or hydroxy methyl groups and transport
competition in relation to tritiated myo-inositol was examined.
Single substitutions competed against tritiated myo-inositol trans-
port, with chlorine and fluorine substitutions competing against
tritiated myo-inositol transport as efficiently as myo-o rscyllo-inositol.
However, double substitutions were not recognized as efficiently,
highlighting the apparent specificity of the transporters.
In conclusion, inositol transporter expression in the brain was
unaltered by amyloid disease pathology, as determined by
comparing SMIT1 versus SMIT2 expression profiles in
TgCRND8 mice. Overall, SMIT1 expression in the brain was
higher than SMIT2, with equivalent expression in the cortex and
hippocampus. Expression of both transporters was observed in all
the brain regions examined and regional expression profiles were
unique. When the inhibition of substrate transport was examined,
SMIT1/2 transported scyllo-inositol as expected, although at a
slower uptake rate than myo-inositol. The findings of this study
suggest that the beneficial effects seen in the preclinical studies on
the efficacy of scyllo-inositol in a Tg mouse model of AD can be
attributed to the expression of the SMIT1/2 transporters in brain
regions susceptible to AD pathology and the steady transport of
scyllo-inositol to those regions to target AD pathology. These results
are particularly important as the intent to advance scyllo-inositol to
Figure 4. scyllo-Inositol-(2-
3H) transport in HEK 293 cells. scyllo-
Inositol transport in the presence of inositol and sugar isomers was
examined by measuring scyllo-inositol-(2-
3H) transport in the presence
of each of those potential substrates. For the control experiment, scyllo-
inositol-(2-
3H) transport was quantified in the absence of any added
compounds. Cells were incubated for 3 hours in medium containing
100 mMo fscyllo-inositol-(2-
3H) in the presence or absence of 10 mM of
potential inositol or sugar isomer transport competitors and the




3H) transport in HEK 293 cells. myo-
inositol transport was examined by measuring uptake of myo-inositol-
(2-
3H) (100 mM) in the presence or absence of 23 different inositols or
sugars (10 mM) over a 3 hour incubation period, after which
radioactivity was measured. For the control experiment, myo-inositol-
(2-
3H) transport was quantified in the absence of any competitive
substrates. (n=3 wells per variable; *=p,0.05).
doi:10.1371/journal.pone.0024032.g005
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summary results of the phase II study [28,29].
Materials and Methods
Ethics Statement
All experiments were performed according to the Canadian
Council on Animal Care guidelines (Protocol #: 20008707).
Materials
All reagents were purchased from Sigma (St. Louis, MO, USA)
unless otherwise noted. epi-Inositol, allo-inositol and cold scyllo–
inositol were acquired from Transition Therapeutics Inc. (Toron-
to, Ontario, Canada). Viburnitol (1-D-3-deoxy-myo-inositol; Cat
#: FC-041), D-Ononitol (1-D-4-O-methyl-myo-inositol; Cat #:
FC-040), Sequoyitol (5-O-methyl-myo-inositol; Cat #: FC-047)
and D-Pinitol (3-O-methyl-D-chiro-inositol; Cat #: FC-026) were
purchased from Industrial Research Ltd. (Lower Hutt, New
Zealand). myo-Inositol-(2-
3H) (3 mCi/mL; Cat #: ART 0116),
scyllo-inositol-(2-
3H) (3 mCi/mL; Cat #: ART 0264) and L-fucose-
(5,6-
3H) (3 mCi/mL; Cat #: ART 0106A) were purchased from
American Radiolabeled Chemicals Inc. (St. Louis, MO, USA).
Mice
TgCRND8 mice were maintained on an outbred C3H/C57Bl6
background. These mice over express the human amyloid
precursor protein gene containing both the Swedish (KM670/
671NL) and Indiana (V717F) mutations under control of the
Syrian hamster prion gene promoter [3]. Mice were kept on a 12-
hour light/dark cycle and given water and standard rodent chow
ad libitum. To quantify inositol transporter expression, TgCRND8
mice and non-Tg littermates at 2, 4 and 6 months of age were
anesthetized with pentobarbital, transcardially perfused with cold
PBS-heparin, after which, the brains were removed and the
cortex, hippocampus and cerebellum dissected for RNA isolation.
Quantification of inositol transporter expression
QPCR was performed using an Applied Biosystems 7500 Real-
Time PCR system and a SYBRH GreenER
TM qPCR SuperMix
Universal kit (Invitrogen, Cat #: 11762). Primers were designed
using the Beacon Designer 7.5 software program for Mac OS X
and are listed in Table 1. Tissue RNA was isolated using phenol/
chloroform extraction and the sample concentrations determined
using a NanoDrop
TM Spectrometer (Thermo Scientific, Wilming-
ton, USA). RNA samples were treated with DNase I (Fermentas,
Cat #: EN0521) to remove any genomic DNA. RNase inhibitor
(Fermentas, Cat #: EO0381) was added to the reaction mixture to
prevent RNA degradation during DNase I treatment. The RNA
concentration was determined and for each sample, 3 cDNA
reactions were performed using a SuperScript III First-Strand
Synthesis SuperMix for qRT-PCR kit (Invitrogen, Cat #: 11752).
Following reverse transcription, residual RNA was removed
through E. coli RNase H treatment and the cDNA concentrations
normalized. For the QPCR reaction, 10 ng of cDNA was used per
well of a 96-well plate. A 2 month, non-tg, kidney, with ideal 260/
280 and 260/230 ratios was selected for use as a between plate
Figure 6. Basic structural model for SMIT1/2 substrate transport competitors. The structures of the substrates which competed for SMIT1/2
myo-inositol-(2-
3H) transport (A), along with the structures of substrates that did not compete, were used to design a basic structural model for
SMIT1/2 substrate transport competitors (B).
doi:10.1371/journal.pone.0024032.g006
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Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) were select-
ed as control genes, following a scan of the National Center for
Biotechnology Information (NCBI), Gene Expression Omnibus
website to confirm stable expression in all three of the brain
regions examined in this study. For analysis, relative quantification
values were normalized to the control genes, inter-plate calibrators
and variations in primer efficiencies, then adjusted to an average
expression level of 1 using the MultiD, GenEx software program
(genex.gene-quantification.info/) for analysis.
Substrate selectivity analysis
Human epithelial kidney (HEK293; ATCC, Cat #: CRL-1573)
cells were cultured in DMEM medium containing 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin. Cells were
plated onto 24-well plates and grown to 90% confluency. Once
90% confluent, cells were washed in PBS (pH 7.0), then incubated




3H) (3 mCi/mL, 100 mM with 0.1% w/v BSA), with or
without a substrate competitor. The substrate competitors
(Figure 2) consisted of either inositol stereoisomers (myo-, scyllo-,
epi-, allo-, muco-, neo-, L-chiro-, or D-chiro-inositol), inositol
derivatives (viburnitol, D-ononitol, sequoyitol, L-quebinchitol or
D-pinitol) or structurally similar sugar substrates (D-glucose, L-
glucose, D-galactose, D-mannose, D-fucose, L-fucose, L-rham-
nose, D-ribose, L-ribose or D-fructose). One well was dedicated to
testing each competitor and triplicate plates were run for each
experiment. Following incubation (3 h, 37uC), cells were washed
twice with PBS containing 1 mM cold myo-inositol, to stop
transporter activity, following which the cells were dissolved using
2% SDS and the radioactivity measured using a scintillation
counter. Competitors were tested either at a fixed concentration
Figure 7. Transport of scyllo-inositol derivatives by SMIT1/2. Further testing of SMIT1/2 myo-inositol transport inhibition was conducted
using derivatives of scyllo-inositol, in which one or two hydroxyl groups were removed or substituted (A). For the control experiment, myo-inositol-
(2-
3H) transport was quantified in the absence of any competitors. An analysis of myo-inositol-(2-
3H) transport in the presence of each of the
compounds, found monodeoxy- but not dideoxy-scyllo-inositol competed for myo-inositol-(2-
3H) transport (B). Single hydroxyl group substitutions
were tolerated in the order chlorine.fluorine.nitrate.hydroxy methyl. (n=3 wells per variable).
doi:10.1371/journal.pone.0024032.g007
Table 1. QPCR primers.
Protein Name Gene Accession # Primers
TATA-box Binding Protein Tbp NM_013684 Forward: GCC TTC CAC CTT ATG CTC AG Reverse: GAG TAA GTC
CTG TGC CGT AAG
Glyceraldehyde 3-phosphate dehydrogenase Gapdh XM_001473623 Forward: AAG AAG GTG GTG AAG CAG GCA TC Reverse: CGA
AGG TGG AAG AGT GGG AGT TG
Sodium/myo-inositol transporter 1 Slc5a3 NM_017391 Forward: CTG TGG TGC TGT GGG ATG ATG Reverse: CCT GCT
GGG TCT GAA CTT TGC
Sodium/myo-inositol transporter 2 Slc5a11 NM_146198 Forward: CAA GGT GGT GAG GGC TAT CC Reverse: CTA TGA CAG
GTT CCG CTT TGC
doi:10.1371/journal.pone.0024032.t001
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derivatives were used to test myo-inositol-(2-
3H) transport require-
ments at a fixed concentration of 2 mM.
Statistical analysis
Statistical analysis was conducted using the Statistical Analysis
System (SAS) and the Graphpad Prism programs. Groups were
compared using a one-way ANOVA. If a significant F score was
observed (p,0.05), a Bonferroni post hoc test was used to compare
groups with the statistical significance, p,0.05.
Supporting Information
Figure S1 A comparison of D- and L-chiro-inositol
inhibition of myo-inositol transport in HEK293 cells.
Based on reduction in myo and scyllo-inositol transport by, D-
chiro-inositol it is recognized by SMIT1/2, while L-chiro-inositol is
not. This finding was examined more closely in HEK293 cells, by
comparing the transport of myo-inositol-(2-
3H) in the presence of
increasing concentrations of D-chiro-inositol (A), to transport
observed in the presence of increasing concentrations of L-chiro-
inositol (B). As expected myo-inositol-(2-
3H) transport was inhibited
by D-chiro-inositol in a concentration dependent manner. In
contrast, L-chiro-inositol did not inhibit myo-inositol-(2-
3H) trans-




3H) transport. L-fucose was found
to be a competitive inhibitor of myo- and scyllo-inositol-(2-
3H)
transport through SMIT1/2. This finding was further examined
by: (A) examining myo-inositol-(2-
3H) transport in the presence of
increasing concentrations of L-fucose. A concentration-dependent
reduction of myo-inositol-(2-
3H) transport was observed. (B)A n
examination of L-fucose-(5,6-
3H) transport in these cells, in the
presence or absence of potential competitive substrates. Only
background radioactivity was observed, with not active transport.
(C) L-fucose-(5,6-
3H) transport was examined in the presence or
absence of D-fucose and increasing concentrations of cold L-
fucose and again only background radioactivity was observed.
(n=3 wells per variable).
(TIF)
Author Contributions
Conceived and designed the experiments: DF Y-QW IA MN JM.
Performed the experiments: DF. Analyzed the data: DF Y-QW MN JM.
Wrote the paper: DF IA MN JM.
References
1. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, et al.
(2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse
Alzheimer phenotype in a mouse model. Nat Med 12: 801–808.
2. Fenili D, Brown M, Rappaport R, McLaurin J (2007) Properties of scyllo-inositol
as a therapeutic treatment of AD-like pathology. J Mol Med 85: 603–611.
3. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, et al. (2001) Early-onset
amyloid deposition and cognitive deficits in transgenic mice expressing a double
mutant form of amyloid precursor protein 695. J Biol Chem 276: 21562–21570.
4. Choi JK, Carreras I, Dedeoglu A, Jenkins BG (2010) Detection of increased
scyllo-inositol in brain with magnetic resonance spectroscopy after dietary
supplementation in Alzheimer’s disease mouse models. Neuropharmacology 59:
353–357.
5. Michaelis T, Helms G, Merboldt KD, Ha ¨nicke W, Bruhn H, et al. (1993)
Identification of Scyllo-inositol in proton NMR spectra of human brain in vivo.
N M R Biomed 6: 105–109.
6. Seaquist ER, Gruetter R (1998) Identification of a high concentration of scyllo-
inositol in the brain of a healthy human subject using 1H- and 13C-NMR. Magn
Reson Med 39: 313–316.
7. Palmano KP, Whiting PH, Hawthorne JN (1977) Free and lipid myo-inositol in
tissues from rats with acute and less severe streptozotocin-induced diabetes.
Biochem J 167: 229–235.
8. Kwon HM, Yamauchi A, Uchida S, Preston AS, Garcia-Perez A, et al. (1992)
Cloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress
protein. J Biol Chem 267: 6297–6301.
9. Hager K, Hazama A, Kwon HM, Loo DD, Handler JS, et al. (1995) Kinetics
and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus
oocytes. J Membr Biol 143: 103–113.
10. Coady MJ, Wallendorff B, Gagnon DG, Lapointe JY (2002) Identification of a
novel Na+/myo-inositol cotransporter. J Biol Chem 277: 35219–35224.
11. Roll P, Massacrier A, Pereira S, Robaglia-Schlupp A, Cau P, et al. (2002) New
human sodium/glucose cotransporter gene (KST1): identification, characteriza-
tion, and mutation analysis in ICCA (infantile convulsions and choreoathetosis)
and BFIC (benign familial infantile convulsions) families. Gene 285: 141–148.
12. Bourgeois F, Coady MJ, Lapointe JY (2005) Determination of transport
stoichiometry for two cation-coupled myo-inositol cotransporters: SMIT2 and
HMIT. J Physiol 563: 333–343.
13. Berry GT, Mallee JJ, Kwon HM, Rim JS, Mulla WR, et al. (1995) The human
osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular
cloning and localization to chromosome 21. Genomics 25: 507–513.
14. Inoue K, Shimada S, Minami Y, Morimura H, Miyai A, et al. (1996) Cellular
localization of Na+/MYO-inositol co-transporter mRNA in the rat brain.
Neuroreport 7: 1195–1198.
15. Liu X, Erikson C, Brun A (1996) Cortical synaptic changes and gliosis in normal
aging, Alzheimer’s disease and frontal lobe degeneration. Dementia 7: 128–134.
16. Kaiser LG, Schuff N, Cashdollar N, Weiner MW (2005) Scyllo-inositol in
normal aging human brain: 1H magnetic resonance spectroscopy study at 4
Tesla. N M R Biomed 18: 51–55.
17. Wang VY, Zoghbi HY (2001) Genetic regulation of cerebellar development. Nat
Rev Neurosci 2: 484–491.
18. Thal DR, Ru ¨b U, Orantes M, Braak H (2002) Phases of A beta-deposition in the
human brain and its relevance for the development of AD. Neurology 58:
1791–1800.
19. Ostlund RE, Jr., Seemayer R, Gupta S, Kimmel R, Ostlund EL, et al. (1996) A
stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells.
Identification with D-chiro-[3-3H]inositol. J Biol Chem 271: 10073–10078.
20. Hakvoort A, Haselbach M, Galla HJ (1998) Active transport properties of
porcine choroid plexus cells in culture. Brain Res 795: 247–256.
21. Bissonnette P, Coady MJ, Lapointe JY (2004) Expression of the sodium-myo-
inositol cotransporter SMIT2 at the apical membrane of Madin-Darby canine
kidney cells. J Physiol 558: 759–768.
22. Aouameur R, Da Cal S, Bissonnette P, Coady MJ, Lapointe JY (2007) SMIT2
mediates all myo-inositol uptake in apical membranes of rat small intestine.
Am J Physiol Gastrointest Liver Physiol 293: G1300–G1307.
23. Klaus F, Palmada M, Lindner R, Laufer J, Jeyaraj S, et al. (2008) Up-regulation
of hypertonicity-activated myo-inositol transporter SMIT1 by the cell volume-
sensitive protein kinase SGK1. J Physiol 586: 1539–1547.
24. Lin X, Ma L, Fitzgerald RL, Ostlund RE, Jr. (2009) Human sodium/inositol
cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells. Arch
Biochem Biophys 481: 197–201.
25. Rubin LJ, Hale CC (1993) Characterization of a Mg-dependent, Na-inositol co-
transport process in cardiac sarcolemmal vesicles. J Mol Cell Cardiol 25:
721–731.
26. Sun Y, Zhang G, Hawkes CA, Shaw JE, McLaurin J, et al. (2008) Synthesis of
scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation.
Bioorg Med Chem 16: 7177–7184.
27. Hawkes CA, Deng LH, Shaw JE, Nitz M, McLaurin J (2010) Small molecule
beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve
cognition and pathology in a mouse model of Alzheimer’s disease. Eur J Neurosci
31: 203–213.
28. Transition Therapeutics Inc website. Available: http://www.transitiontherapeutics.
com/media/archive.php. Accessed 2011 August 5.
29. Elan Corporation Website. Available: http://newsroom.elan.com/phoenix.
zhtml?c=88326&p=irol-newsArticle&ID=1458241. Accessed 2011, August 5.
Inositol Transporters in AD-Like Pathology
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e24032